INeo-Epp: T-cell HLA class I immunogenic or neoantigenic epitope prediction via random forest algorithm based on sequence related amino acid features

Guangzhi Wang[1,2¶], Huihui Wan[2,3¶], Xingxing Jian[2,4], Jian Ouyang[2], Yuyu Li[1], Xiaoxiu Tan[3], Yong Xu[3], Yong Zhao[1*], Yong Lin[3*], Lu Xie[1,2*]

[1] College of Food Science and Technology, Shanghai Ocean University, Shanghai, China

[2] Shanghai Center for Bioinformation Technology, Shanghai Academy of Science and Technology, Shanghai, China

[3] School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China

[4] Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education; Key Laboratory of Carcinogenesis, National Health and Family Planning Commission, Xiangya Hospital, Central South University, Changsha, China.

* Corresponding author

E-mail: yzhao@ shou.edu.cn (YZ)

E-mail: yong_lynn@163.com (YL)

E-mail: luxiex2017@outlook.com (LX)

¶These authors contributed equally to this work.

Abstract

In silico T-cell epitope prediction plays a key role in immunization experiments design and vaccine preparation. In this study, classification models based on random forests algorithm were trained by use of experimental human leukocyte antigen class I (HLA-I) presenting T-cell peptides data, in which several characteristics were constructed as immunogenicity features, including amino acid sequence characteristics, peptide entropy, eluted ligand likelihood percentile rank (EL %Rank) score and score of immunogenic peptide. The classification result for the antigen epitopes outperformed the previous research (AUC=0.81, external validation data set AUC=0.77). As mutational epitopes generated by the coding region contain only the alterations of one or two amino acids, we assume that these characteristics might also be applied to the classification of the endogenic mutational epitopes named 'neoantigens'. Based on

mutation information and sequence related amino acid characteristics, a prediction model of neoantigen was established as well (AUC=0.78). Further, a web-based tool was developed for the prediction of either human antigen epitope or neoantigen epitope (http://www.biostatistics.online/INeo-Epp/antigen.php). Overall, by analyzing amino acid distribution in T-cell receptor (TCR) contact sites, we found that TCR prefers to recognize the hydrophobic amino acids. This work may provide a new insight for T-cell recognition of antigen peptides.

Author summary

Currently, most epitope prediction researches focus on peptides processing and presenting, such as proteasomal cleavage, transporter associated with antigen processing (TAP) and major histocompatibility complex (MHC) combination. To date, however, the immunogenicity mechanism of epitopes remains unclear. It is generally agreed upon that T-cell immunogenicity may be influenced by foreignness, accessibility, molecular weight, molecular structure, molecular conformation, chemical properties and physical properties of target peptides in different degrees. Here, we first collected quite an amount of experimental HLA-I T-cell peptides data, as well as the potential immunogenic amino acid features. Subsequently, based on the random forest algorithm, we successfully constructed the separate prediction models for T cell immunogenic HLA-I presenting antigen and neoantigen epitopes. Furthermore, we built a web-based tool to facilitate the prediction of HLA-I T-cell immunogenic epitopes.

Introduction

An antigen is consisted of several epitopes, which can be recognized either by B-

54 or T-cells and/or molecules of the host immune system. However, usually, a few amino
55 acid residues that comprise an epitope are sufficient to elicit an immune response [1].
56 MHC-I (HLA-I in human) antigen peptides are processed and presented as follows: (1)
57 cytosolic and nuclear proteins are cleaved to short peptides by intracellular proteinases;
58 (2) some are selectively transferred to endoplasmic reticulum (ER) by TAP transporter,
59 and subsequently are treated by endoplasmic reticulum aminopeptidase; (3) antigen
60 presenting cells (APCs) present peptides possessed to 8-11 AA (amino acid) residues
61 on MHC class I molecules to CD8+ T cells [2]. So far, several software have been
62 developed to predict the antigen processing and presentation, including NetChop [3],
63 NetCTL [4], NetMHCpan [5], MHCflurry [6]. However, statistically, approximately
64 only 1% of the predicted binding peptide-MHC complexes (p-MHC) can eventually
65 cause immunogenicity [7]. Although the recognition and amplification of T-cells may
66 benefit from the development of T-cell receptor (TCR) sequencing, the cycle of vaccine
67 development and immunization research is extended. Thus, an effective identification
68 method follow-up the above software is urgently needed to shorten the whole cycle.
69 Nowadays, many experimental human epitopes may be acquired from the immune
70 epitope database (IEDB) [8], which makes it feasible to mathematically predict human
71 epitopes. Even if IEDB provides us a wide range of information on T cell epitopes, a
72 high degree of MHC polymorphism brings forward a severe challenge for T-cell
73 epitope prediction. HLA molecules have hundreds of different variants [9].
74 Experimentally, many infrequent HLA subtypes peptides (*e.g.* B55, B63) with
75 uneven positive and negative distributions are not conducive to analyze the potential
76 deviation existed in TCR recognition owing to various HLA presented peptides. A
77 general analysis of all HLA presented peptides, ignoring the pattern of TCR recognition
78 of specific HLA, may result in a lower prediction.

79 Due to the intensive study on HLA, HLA supertype has been proposed. Sette *et al.*
80 [10] classified, for the first time, overlapping peptide binding repertoires into nine
81 major functional HLA supertypes (A1, A2, A3, A24, B7, B27, B44, B58, B62). In 2008,
82 John Sidney *et al* [11] made a further supplement, in which over 80% of the 945
83 different HLA-A and -B alleles can be assigned to the original nine supertypes. It has
84 not been reported whether peptides presented by different HLA alleles influence TCR
85 recognition. Hence，we collected experimental epitopes according to HLA alleles for
86 analyzing.

87 Screening of mutant and abnormally expressed epitopes are crucial in tumor
88 immunotherapy. In 2017, Ott PA *et al.* [12] and Sahin *et al* [13]. confirmed that peptides
89 and RNA vaccines made up of neoantigens in melanoma can stimulate and proliferate
90 CD8+ and CD4+ T cells. Neoantigen vaccination not only can expand the existing
91 specific T cells, but also induce a wide range of novel T-cell specificity in cancer
92 patients and enhance tumor suppression [14]. Meanwhile, a tumor can be better
93 controlled by the combination therapy of neoantigen vaccine and programmed cell
94 death protein 1 (PD-1)/PD1 ligand 1(PDL-1) therapy [15-16]. However, a considerable
95 amount of identified candidate neoantigens in the process of sequencing recognition of
96 somatic cell mutations were false positive, which would fail to stimulate TCR
97 recognition and immune response. This is undoubtedly a disadvantage for designing
98 vaccines against neoantigens.

99 In this study, based on the collection of the validated HLA-I T-cell peptides,
100 including antigens and neoantigens, we discovered several effective classification
101 features and successfully constructed the classification models for antigens and
102 neoantigens, respectively. Furthermore, a web-based tool, INeo-Epp (immunogenic and
103 neoangtigenic epitope prediction), was built for separate prediction of human antigen

104 and neoantigen epitopes.

105

106 ## Results

107 **Immunogenic and non-immunogenic epitopes**

108 Peptides that can promote cytokines proliferation are considered as immunogenic
109 epitopes. However, non-immunogenic epitopes may result from the following reasons:
110 a) p-MHC truly unrecognized by TCR; b) peptides unpresented by MHC (quantitatively
111 expressed as %rank>2); c) negative selection/clonal presentation induced by excessive
112 similarity with autologous peptides [17]. In this work, to further study the recognition
113 preferences of T cells, >2 %rank and 100% matching human GRCh38 peptide
114 sequences were removed from the definition of non-immunogenic peptides.

115

116 **Data statistics**

117 In this study, 11,297 validated epitopes and non-epitopes with the length of 8-11
118 amino acids were collected from IEDB. T-cell responses include activation,
119 cytotoxicity, proliferation, IFN-γ release, TNF release, granzyme B release, IL-2
120 release, IL-10 release. Seventeen different HLA alleles were collected (Fig 1A), and
121 the detailed antigen lengths distribution are shown in (Fig 1B). Besides, we also
122 collected the neoantigen data from 12 publications, including 2837 non-epitopes and
123 164 epitopes (Fig 1C), and the detailed neoantigen lengths distribution are shown in
124 (Fig 1D).



Figure1：Epitope peptides composition and amino acid lengths distribution.

(A) Detailed seventeen HLA alleles of antigen peptides data distribution and each HLA allele positive and negative data proportion and the corresponding HLA frequency in Asian, Black, Caucasian. (B) Antigen peptides proportion of 8-11 AA lengths. (C) Distribution of HLA alleles of neoantigen peptides. (D) Neoantigen peptides proportion of 8-11 AA lengths.

Furthermore, we analyzed the position-related amino acid arrangement in antigen epitopes. The result showed that leucine was strongly preferred in all the positions of antigen epitope, however, tryptophan, histidine, cysteine were the least preferred (Fig2 A). TCR contact position plays a crucial role in the analysis of immunogenicity. As TCRs might be more sensitive to some amino acids, the amino acids preference in antigen epitope peptide and antigen non-epitope peptide was further analyzed after

139 excluding anchor sites. We found that a TCR tends to identify the hydrophobic amino
140 acids (Fig 2B). For example, 70% of amino acids that occur more frequently in
141 immunogenicity epitopes are hydrophobic (W, P, A, V, L). Charged amino acids (*e.g.*
142 D, K) are enriched in non-epitopes, and amino acids with more complex R group
143 structure frequently occur in non-epitopes. Based on the above, the amino acid
144 distribution difference at the TCR contact sites was regarded by us as one of the
145 immunogenicity features (*i.e.* score for immunogenic peptide (C22)).



146

147

148 **Figure 2: Antigen epitope amino acid distribution difference in P1-P11, and amino**
149 **acid distribution frequency in TCR contact site of antigen epitope and non-epitope.**

150 (A) The proportion of amino acids at each position of epitope and non-epitope peptides
151 in antigen peptides, and the higher position the more frequency. (B) Frequency
152 distribution of amino acids at solvent-exposed positions in antigen epitope and non-
153 epitope peptides, and the amino acids below the dotted line are preferred by the epitope.
154

155 **Classification prediction model for antigen epitopes**

156 We constructed the features of peptides on the basis of the characteristics of amino
157 acids (see Materials and Methods section: Characteristics Calculation of peptides based
158 on amino acids). All amino acid characteristics were selected from Protscale [18] in
159 ExPASy (SIB bioinformatics resource portal). The 21 involved features are as follows:
160 Kyte–Doolittle numeric hydrophobicity scale (C1) [19], molecular weight (C2),
161 bulkiness (C3) [20], polarity (C4) [21], recognition factors (C5) [22], hydrophobicity
162 (C6) [23]，retention coefficient in HPLC (C7) [24], ratio hetero end/side (C8) [21],
163 average flexibility (C9) [25], beta-sheet (C10) [26], alpha-helix (C11) [27]，beta-turn
164 (C12) [27]，relative mutability (C13) [28], number of codon(s) (C14), refractivity
165 (C15) [29], transmembrane tendency (C16) [30]，%accessible residues (C17) [31]，
166 average area buried (C18) [32]，conformational parameter for coil (C19) [27]， total
167 beta-strand (C20) [33]，parallel beta-strand (C21) [33] (see Table S4 in detail). Also,
168 score for immunogenic peptide (C22), peptide entropy (C23) [34] and %rank (C24)
169 were also taken into consideration. Together, 24 immunogenic features were collected,
170 and all features were retained for antigen epitopes prediction after screening using R
171 package Buroat [35]. Compared to other characteristics, score for immunogenic peptide
172 and %rank have higher impacts, suggesting they have more significant power on
173 antigen epitopes classification (Firure3 A).

The receiver operator characteristic (ROC) curve of models are shown in Fig 4. The five-fold cross validation AUC was 0.81 in the prediction model for antigen epitope (line in red Fig3 B) and the externally validated AUC was 0.75 (line in purple Fig4 C). Here, we tried to remove HLA supertypes (not included in training set) data from the externally validated antigen data and, the AUC, specificity, and sensitivity were increased to 0.78, 0.71, and 0.72, respectively. (line in pink Fig4 C). This, to some extent, verifies our conjecture about TCR specific recognition of different HLA alleles presenting peptides.



Figure 3: Feature selection in antigen epitopes and ROC curves of antigen epitopes classification. (A) Twenty four features were screened and retained, the features on the right of the dotted line are effective. (B) The line in blue represents antigen epitopes without screening; the line in green represents selection with the deletion of %rank>2 non-epitope; and the line in red represents selection with the deletion of the non-epitopes 100% matching human GRCh38 peptides sequence. (C) The ROC curves of external verification set, line in purple represents modeling using antigen epitopes without filtering, the line in pink represents using antigen epitopes removing non-

191 epitopes %rank>2 and HLA supertypes (not encountered in training set).

192

193 **Classification prediction model for neoantigen epitopes**

194 Neoantigens derived from somatic mutations are different from the wild peptide
195 sequences. Therefore, some mutation-related characteristics were also taken into
196 account. For instance, hydrophobic difference before and after mutation (C25),
197 differential agretopicity index (DAI, C26) [36] and whether the mutation position was
198 anchored (C27). Finally, 27 features were selected for the neoantigen model. However,
199 only 25 neoantigen related features were retained after running Buroat, because C25
200 and C27 were removed. Also, %rank showed a marked effect (Fig 4A). in the five-fold
201 cross-validation of the prediction model for neoantigen epitopes, AUC was 0.78 (Fig
202 4B).



203

204

205 **Figure 4: Feature selection in neoantigen epitopes and ROC curves of neoantigen**
206 **epitopes classification.** (A) Twenty seven features were screened and the 25 features
207 on the right of the dotted line were reserved for modeling in random forest algorithm.
208 (B) ROC curves of neoantigen epitopes classification.

209

Web server for TCR epitope prediction

Based on these above-mentioned validated features, we established a web server for TCR epitope prediction, named INeo-Epp. This tool can be used to predict both immunogenic antigen and neoantigen epitopes. For antigen, the nine main HLA supertypes can be used. We recommend the peptides with the lengths of 8-12 residues, but not less than 8. N-terminal, position 2, C-terminal were treated as anchored sites by default. A predictive value greater than 0.5 is considered as positive immunogenicity (P). Please make sure that HLA-subtype must match your peptides. When HLA-subtype mismatches, the different %rank value may strongly influence the results. Additionally, the neoantigen model requires providing wild and mutated sequences at the same time to extract mutation associated characteristics, and currently only immunogenicity prediction for neoantigens of single amino acid mutations are supported. You can use example option to test the INeo-Epp (http://www.biostatistics.online/INeo-Epp/antigen.php).

Discussion

Because of the complexity of antigen presenting and TCR binding, the mechanism of TCR recognition has not been clearly revealed. In 2013, J. A. Calis [37] developed a tool for epitope identification of mice and humans (AUC = 0.68). Although mice and human beings are highly homologous, the murine epitopes may very likely cause deviation in identifying human epitopes. Inspired by J. A. Calis, our research focused on human beings' epitopes and were conducted in a larger data set. In our study, the TCR recognized immunogenic epitope prediction AUC is increased to 0.81.

By analyzing epitope immunogenicity from the perspective of amino acid

molecular composition, we observed that TCRs do have a preference for hydrophobic amino acid recognition. For short peptides presented by different HLA supertypes, TCRs may have different identification patterns. The immunogenicity prediction based on all HLA-presenting peptides may affect the accuracy of the prediction results. That is, the prediction results of specified HLA-presenting peptides may be better. Recently, Céline M. Laumont [38] demonstrated that noncoding regions aberrantly expressed tumor-specific antigens (aeTSAs) may represent ideal targets for cancer immunotherapy. These epitopes can also be studied in the future.

However, for neoantigens prediction, the positive prediction rate is not as good (AUC is 0.78 and no external validation), because relevant and available experimental data of TCR recognized neoepitopes are limited. The immunogenic neoantigen prediction model remains to be improved as more data will be gathered. Besides, a TCR sequencing database would be needed to study the relationship between TCRs and epitopes from a deeper structure. More relevant amino acid properties and structural features may remain to be discovered for further mathematical analysis. We believe that in the age of biological systems data explosion, mathematical calculation is a good way to derive biological significance. With the development of machine learning and deep learning, we expect the prediction of neoantigen immunogenicity will be continually improved.

Neoantigen prediction is the most important step in the preparation of neoantigen vaccine. Bioinformatics methods can be used to extract tumor mutant peptides and predict neoantigens. Most current strategies end in presenting peptides predictions and among the results of these predictions, in the end, less than 10 neoantigens might be discovered, but it is time-consuming and costly to experimentally eliminate the false positively predicted peptides. Our methods in this study and the INeo-Epp tool may

259 help eliminate a large number of false positive antigen/neoantigen peptides, and greatly
260 reduce the amount of candidates to be verified by experiments.
261 In summary, this study provides an inference from the immunogenicity
262 classification prediction of antigens to neoantigens, and the INeo-Epp can be applied
263 not only to identify putative antigens, but also to identify putative neoantigens.
264

265 Materials and Methods

266 Generation of data sets

267 Antigen epitope data were collected from IEDB (Linear epitope, Humans, T cell
268 assays, MHC class I, any disease were chosen). Data collection criteria: each HLA
269 subtype quantity >50 and HLA frequency >0.5% (refer to allele frequency database
270 [39]) (Table 1, check Table S1 for detailed information).
271

272 TABLE 1| Summary of IEDB epitope data

HLA supertype	IEDB HLA data	Number		HLA allele frequency Asian / Black / Caucasian	Motif view
		Negative	Positive		
A1	A01:01	811	103	0.154 / 0.046 / 0.164	1-2(ST)-3-4-5-6-7-8-9(Y)
	A26:01	83	19	0.041 / 0.014 / 0.030	1(DE)-2(ITV)-3-4-5-6-7-8-9(FMY)
A2	A02:01	1883	1580	0.049 / 0.123 / 0.275	1-2(LM)-3-4-5-6-7-8-9(ILV)-10(V)
A3	A11:01	196	174	0.139 / 0.014 / 0.060	1-2(IMSTV)-3-4-5-6-7-8-9(K)-10(K)
	A03:01	1400	169	0.063 / 0.083 / 0.139	1-2(ILMTV)-3-4-5-6-7-8-9(K)-10(K)
A24	A24:02	207	219	0.136 / 0.024 / 0.084	1-2(WY)-3-4-5-6-7-8-9(FIW)
	A23:01	1138	12	0.006 / 0.109 / 0.019	1-2(WY)-3-4-5-6-7-8-9-10(F)
B7	B35:01	63	248	0.062 / 0.068 / 0.055	1-2(P)-3-4-5-6-7-8-9(FMY)
	B07:02	523	244	0.034 / 0.005 / 0.0143	1-2(p)-3-4-5-6-7-8-9(FLM)
	B51:01	13	51	0.074 / 0.021 / 0.047	1-2(P)-3-4-5-6-7-8-9(IV)
B8	B08:01	317	195	0.036 / 0.037 / 0.114	1-2-3-4-5(HKR)-6-7-8-9(FILMV)
B27	B27:05	100	86	0.008 / 0.008 / 0.037	1(RY)-2(R)-3(FMLWY)-4-5-6-7-8-9
B44	B37:01	1036	10	0.034 / 0.005 / 0.014	-
	B40:01	67	65	0.022 / 0.012 / 0.052	-
	B44:02	73	66	0.008 / 0.020 / 0.095	1-2(E)-3-4-5-6-7-8-9(FIWY)
B58	B58:01	11	62	0.041 / 0.037 / 0.007	1-2(AST)-3-4-5-6-7-8-9(W)
B62	B15:01	3	70	0.016 / 0.010 / 0.060	1-2(LMQ)-3-4-5-6-7-8-9(FY)
Total		7924	3373		
Remove negative %rank>2		5123	3373		
Remove negative human 100% similar		4943	3373		

273

274 The validation dataset was collected from seven published independent human
275 antigen studies [40-46], consisting of 577 non-immunogenic epitopes and 85
276 immunogenic epitopes (Table 2, S2 Table)

TABLE2 | validated peptides data included in this study

Publication time	PMID	Author	non-epitopes	epitopes
2013	23580623	Weiskopf et al	477	42
2018	29397015	Hendrik Luxenburger et al	100	26
2018	30260541	Youchen Xia et al	-	1
2018	30487281	Hawa Vahed et al	-	4
2018	30518652	Atefeh Khakpoor et al	-	2
2018	30587531	Alina Huth et al	-	4
2018	30815394	Solomon Owusu Sekyere et al	-	6
Total			577	85
Remove negative %rank >2 and HLA supertypes (not in training set)			321	69

The neoantigen data were collected from 11 publications [15,48-57] and IEDB mutational epitopes, and 13 published data sets collected by Anne-Mette B in one publication [47] in 2017, see Table 3, S3 Table for details.

TABLE 3| Neoantigen data included in this study

Publication time	PMID	Author	Tumor Type	Non-immunogenic neo-epitopes	Immunogenic neo-epitopes	T-cell assay
2013-12	24323902	Darin A. W et al.	Ovarian Cancer	—	1	ELISPOT
2015-9	26359337	Eliezer M et al.	Melanoma	—	18	Clinical benefit
2015-11	26752676	Takahiro K et al.	Lung adenocarcinoma	—	4	—
2016-1	26901407	Alena Gros et al.	Melanoma	12	14	ELISPOT
2016-5	27198675	Erlend Strønen et al.	Melanoma	1134	16	CTL clone
2016-12	28405493	Annika Nelde et al.	Lymphoma	—	2	ELISPOT
2017-6	28619968	Xiuli Zhang et al.	Breast cancer	—	4	Flow cytometry
2017-10	29104575	Markus M et al.	Melanoma	10	16	—
2017-11	29187854	Anne-Mette B et al.	Polytype	1874	42	ELISPOT et al.
2017-11	29132146	Vinod P. B et al.	pancreatic	—	10	Flow Cytometry
2018-5	29720506	Tatsuo Matsuda et al.	Ovarian Cancer	—	3	ELISPOT
2018-12	29409514	Sonntag et al.	pancreatic ductal carcinoma	—	3	Flow Cytometry
2018-10	30357391	Randi Vita et al.	—	6	35	—
Total				3030	168	
Remove duplication				2837	164	
Remove negative %rank>2 and human 100% similar				1697	164	

Feature calculation

Characteristics calculation of peptides based on amino acid sequences. The formula for calculating peptide characteristics is shown in (1). P_N, P_2, P_C are considered to be embedded in HLA molecules and no contact with TCRs, so they're not evaluated.

$$P_c = \{ \sum_{x \in Pos(P)}^{x \notin (N,2,C)} P_{A_c} \} \Big/ (len(P) - 3) \quad (1)$$

$\boldsymbol{P}$, peptide. $\boldsymbol{c}$, characteristic. Where $\boldsymbol{P_c}$ represents characteristics of peptides. $\boldsymbol{A}$, amino acid. $\boldsymbol{N}$, N-terminal in a peptide. $\boldsymbol{C}$, C-terminal in a peptide. Pos, amino acid position in peptide. Where $\boldsymbol{P_{Ac}}$ represents characteristics of amino acids in peptides.

Score for immunogenic peptide (C22). Amino acid distribution frequency differences between immunogenicity and non-immunogenic peptides at TCR contact sites were considered as a feature (2).

$$P_{score} = \sum_{x \in Pos(P)}^{x \notin (N,2,C)} \{ P_{ie^+}(f'_A) - P_{ie^-}(f'_A) \} \quad (2)$$

$\boldsymbol{P_{ie}^+}$, immunogenic peptides. $\boldsymbol{P_{ie}^-}$, non-immunogenic peptides. $\boldsymbol{f'_A}$, amino acid frequency in TCR contact position. Where $\boldsymbol{P_{ie+}(f'_A)}$ represents frequency of amino acids in immunogenic peptides at TCR contact sites.

Calculating peptide entropy (C23). peptide entropy [58] was used as a feature (3).

$$P_H = \{ - \sum_{x \in Pos(P)}^{x \notin (N,2,C)} P_{f_A} * \log_2(P_{f_A}) \} \Big/ (len(P) - 3) \quad (3)$$

$\boldsymbol{P_H}$, peptide entropy. $\boldsymbol{f_A}$, amino acid frequency in human GRCh38 peptides. Where $\boldsymbol{P_{fA}}$ represents the frequency in human GRCh38 peptides of amino acids in epitope peptides.

%rank score (C24). HLA binding prediction were run by netMHCpan4.0 in which %rank was recommended as evaluation standard，%rank<0.5 as strong binders, 0.5<%rank<2 as weak binders, %rank>2 as no binders.

Cross-validation, feature selection, random forests and ROC generation.

The cross-validation were generated in R using the package caret [59] (method = "repeatedcv", number = 5, repeats = 3). The feature screening result were generated in R using the package Buroat (a feature selection method). R package randomForest [60] was used for training data (mtry=14 for antigen epitope, mtry=15 for neoantigen, the remaining parameter use default values). R package ROCR was used [61] for drawing ROC.

Analysis and statistics

A python script was used for calculating peptide characteristics and extracting mutation information. Models were built using R.

Acknowledgments

This work was funded by the National Natural Science Foundation of China (No. 31870829), Shanghai Municipal Health Commission, and Collaborative Innovation Cluster Project (No. 2019CXJQ02). We sincerely thank Menghuan Zhang, Guangrong Qin, Hong Li and Qibing Leng for their valuable advice.

Author Contributions

Conceptualization: Lu Xie, Guangzhi Wang

Funding acquisition: Lu Xie

Formal Analysis: Guangzhi Wang

Investigation: Guangzhi Wang

Methodology: Guangzhi Wang

Software: Huihui Wan, Ouyang Jan, Guangzhi Wang

Supervision： Yuyu Li, Xiaoxiu Tan, Yong Xu, Yong Zhao, Yong Lin

Writing – original draft: Guangzhi Wang**.**

Writing – review & editing: Lu Xie, Xingxing Jian**.**

Competing interests

The authors have declared that no competing interests exist.

References

1. Desai DV, Kulkarni-Kale U. T-cell epitope prediction methods: an overview. Methods in molecular biology (Clifton, NJ). 2014;1184:333-64.
2. Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. Nature. 1992;357(6377):375-9.
3. Kesmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein engineering. 2002;15(4):287-96.
4. Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, Lund O, et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. European journal of immunology. 2005;35(8):2295-303.
5. Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. Journal of immunology (Baltimore, Md : 1950). 2017;199(9):3360-8.
6. O'Donnell TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U, Hammerbacher

358 J. MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. Cell systems.
359 2018;7(1):129-32.e4.
360 7. Kristensen VN. The Antigenicity of the Tumor Cell - Context Matters. The New
361 England journal of medicine. 2017;376(5):491-3.
362 8. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The
363 Immune Epitope Database (IEDB): 2018 update. Nucleic acids research. 2019;47(D1):
364 D339-d43.
365 9. Reche PA, Reinherz EL. Definition of MHC supertypes through clustering of MHC
366 peptide-binding repertoires. Methods in molecular biology (Clifton, NJ). 2007;409:
367 163-73.
368 10. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast
369 preponderance of HLA-A and -B polymorphism. Immunogenetics. 1999;50(3-4):201-
370 11. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised
371 and updated classification. BMC immunology. 2008;9:1.
372 12. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic
373 personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-
374 21.
375 13. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al.
376 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity
377 against cancer. Nature. 2017;547(7662):222-6.
378 14. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines
379 for cancer. Nature reviews Immunology. 2018;18(3):168-82.
380 15. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al.
381 Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science
382 (New York, NY). 2015;350(6257):207-11.

383 16. Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens Generated by
384 Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.
385 Frontiers in immunology. 2017;8:1679.
386 17. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the
387 thymus for positive selection and central tolerance induction. Nature reviews
388 Immunology. 2009;9(12):833-44.
389 18. Ramsby M, Makowski G. The Proteomics Protocols Handbook2005. 37-48 p.
390 19. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of
391 a protein. Journal of molecular biology. 1982;157(1):105-32.
392 20. Zimmerman JM, Eliezer N, Simha R. The characterization of amino acid sequences
393 in proteins by statistical methods. Journal of theoretical biology. 1968;21(2):170-201.
394 21. Grantham R. Amino acid difference formula to help explain protein evolution.
395 Science (New York, NY). 1974;185(4154):862-4.
396 22. Fraga SJCJoC. Theoretical prediction of protein antigenic determinants from
397 amino acid sequences. 1982;60(20):2606-10.
398 23. Sweet RM, Eisenberg D. Correlation of sequence hydrophobicities measures
399 similarity in three-dimensional protein structure. Journal of molecular biology.
400 1983;171(4):479-88.
401 24. Meek JL. Prediction of peptide retention times in high-pressure liquid
402 chromatography on the basis of amino acid composition. Proceedings of the National
403 Academy of Sciences of the United States of America. 1980;77(3):1632-6.
404 25. Rose GD, Geselowitz AR, Lesser GJ, Lee RH, Zehfus MHJS. Hydrophobicity of
405 amino acid residues in globular proteins. 1985;229(4716):834-8.
406 26. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their
407 amino acid sequence. Advances in enzymology and related areas of molecular biology.

408 1978;47:45-148.
409 27. Deléage G, Roux BJPE. An algorithm for protein secondary structure prediction
410 based on class prediction. 1987;1(4):289.
411 28. Hersh RTJJoMC. Atlas of Protein Sequence and Structure, 1966. 1965;13(2):337-.
412 29. Jones DD. Amino acid properties and side-chain orientation in proteins: a cross
413 correlation appraoch. Journal of theoretical biology. 1975;50(1):167-83.
414 30. Zhao G, London E. Strong correlation between statistical transmembrane tendency
415 and experimental hydrophobicity scales for identification of transmembrane helices.
416 The Journal of membrane biology. 2009;229(3):165-8.
417 31. Janin J. Surface and inside volumes in globular proteins. Nature.
418 1979;277(5696):491-2.
419 32. Green JR, Korenberg MJ, David R, Hunter IW. Recognition of adenosine
420 triphosphate binding sites using parallel cascade system identification. Annals of
421 biomedical engineering. 2003;31(4):462-70.
422 33. Lifson S, Sander C. Antiparallel and parallel beta-strands differ in amino acid
423 residue preferences. Nature. 1979;282(5734):109-11.
424 34. Shannon CEJBSTJ. A mathematical theory of communication. 1948;27(4):623-56.
425 35. Kursa MB, Rudnicki WRJJoSS. Feature Selection with Boruta Package.
426 2010;36(11):1-13.
427 36. Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, et al.
428 Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to
429 predict anticancer immunogenicity. The Journal of experimental medicine.
430 2014;211(11):2231-
431 37. Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, et al.
432 Properties of MHC class I presented peptides that enhance immunogenicity. PLoS

433 computational biology. 2013;9(10): e1003266.
434 38. Laumont CM, Vincent K, Hesnard L, Audemard E, Bonneil E, Laverdure JP, et al.
435 Noncoding regions are the main source of targetable tumor-specific antigens. Science
436 translational medicine. 2018;10(470).
437 39. Gonzalez-Galarza FF, McCabe A, Melo Dos Santos EJ, Takeshita L, Ghattaoraya
438 G, Jones AR, et al. Allele Frequency Net Database. Methods in molecular biology
439 (Clifton, NJ). 2018;1802:49-62.
440 40. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN,
441 et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-
442 linked protective role for CD8+ T cells. Proceedings of the National Academy of
443 Sciences of the United States of America. 2013;110(22):E2046-53.
444 41. Luxenburger H, Grass F, Baermann J, Boettler T, Marget M, Emmerich F, et al.
445 Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus
446 genotype 1 versus 4. Journal of viral hepatitis. 2018;25(7):779-90.
447 42. Xia Y, Pan W, Ke X, Skibbe K, Walker A, Hoffmann D, et al. Differential escape
448 of HCV from CD8(+) T cell selection pressure between China and Germany depends
449 on the presenting HLA class I molecule. Journal of viral hepatitis. 2019;26(1):73-82.
450 43. Vahed H, Agrawal A, Srivastava R, Prakash S, Coulon PA, Roy S, et al. Unique
451 Type I Interferon, Expansion/Survival Cytokines, and JAK/STAT Gene Signatures of
452 Multifunctional Herpes Simplex Virus-Specific Effector Memory CD8(+) TEM Cells
453 Are Associated with Asymptomatic Herpes in Humans. Journal of virology. 2019;93(4).
454 44. Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, et al. Spatiotemporal
455 Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.
456 Journal of virology. 2019;93(4).
457 45. Huth A, Liang X, Krebs S, Blum H, Moosmann A. Antigen-Specific TCR

458 Signatures of Cytomegalovirus Infection. Journal of immunology (Baltimore, Md :
459 1950). 2019;202(3):979-90.
460 46. Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, et
461 al. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.
462 Liver cancer. 2019;8(1):41-65.
463 47. Bjerregaard AM, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z, et al. An
464 Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes. Frontiers in
465 immunology. 2017;8: 1566.
466 48. Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, et al.
467 Surveillance of the tumor mutanome by T cells during progression from primary to
468 recurrent ovarian cancer. Clinical cancer research: an official journal of the American
469 Association for Cancer Research. 2014;20(5):1125-34.
470 49. Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, et
471 al. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-
472 Based Immunotherapy of Lung Cancer. Journal of thoracic oncology : official
473 publication of the International Association for the Study of Lung Cancer.
474 2016;11(3):324-33.
475 50. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective
476 identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma
477 patients. Nature medicine. 2016;22(4):433-8.
478 51. Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, et al.
479 Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science
480 (New York, NY). 2016;352(6291):1337-41.
481 52. Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, et al. HLA
482 class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma

483 immunotherapy. Oncoimmunology. 2017;6(3): e1219825.
484 53. Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, et al. Breast Cancer
485 Neoantigens Can Induce CD8(+) T-Cell Responses and Antitumor Immunity. Cancer
486 immunology research. 2017;5(7):516-23
487 54. Muller M, Gfeller D, Coukos G, Bassani-Sternberg M. 'Hotspots' of Antigen
488 Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen
489 Prioritization. Frontiers in immunology. 2017;8: 1367.
490 55. Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al.
491 Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
492 Nature. 2017;551(7681):512-6.
493 56. Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, et al. Induction of
494 Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-
495 Engineered T Cells for Ovarian Cancer. Clinical cancer research: an official journal of
496 the American Association for Cancer Research. 2018;24(21):5357-67.
497 57. Sonntag K, Hashimoto H, Eyrich M, Menzel M, Schubach M, Docker D, et al.
498 Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive
499 patient with metastasized pancreatic ductal carcinoma treated with individualized,
500 neoepitope-derived multipeptide vaccines: a case report. Journal of translational
501 medicine. 2018;16(1):23.
502 58. Shannon CEJBSTJ. A mathematical theory of communication. 1948;27(4):623-56.
503 59. Kuhn MJASCL. Caret: Classification and regression training. 2015;129(1):291–
504 295.
505 60. Liaw A, Wiener M. Classification and Regression by RandomForest.2001.
506 61. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier
507 performance in R. Bioinformatics (Oxford, England). 2005;21(20):3940-1.

508 ## Supporting information captions

509 S1 Table **IEDB antigen epitopes summary.** Detailed description of 17 HLA molecules
510 which collected from IEDB. (XLSX)

511 S2 Table **External validation antigen epitopes summary.** Epitope details of 7
512 publications. (XLSX)

513 S3 Table **Neoantigen epitopes summary.** Epitope details of 13 publications. (XLSX)

514 S4 Table **Summary of amino acid characteristics.** For all amino acid characteristics
515 (n=21) that are described in the ExPASy. (XLSX)


A
Asian
Black
Caucasian
B*58:02
B*51:01
B*44:02
B*40:01
B*37:01
B*27:05
B*15:01
B*35:01
B*08:01
B*07:02
A*26:01
A*24:02
A*23:01
A*11:01
A*03:01
A*02:01
A*01:01
Allele frequency(%)
10 20
negative
positive
0
500
1000
1500
2000
2500
3000
B
11 2%
8 3%
10 31%
9 64%
C
1000
800
600
400
200
0
A01:01
A02:01
A02:05
A03:01
A11:01
A23:01
A24:02
A26:01
A30:01
A30:02
A31:01
A32:01
A33:01
A33:03
A68:01
A68:12
B07:02
B08:01
B15:01
B15:17
B18:01
B27:05
B35:01
B35:03
B38:01
B39:01
B44:02
B44:03
B51:01
C02:02
C03:03
C03:04
C05:01
C07:01
C12:03
C14:02
C14:03
C16:01
D
8 2%
11 26%
9 39%
10 33%


A
Probability
1.00
0.75
0.50
0.25
0.00
1 2 3 4 5 6 7 8 9 10 11
chemistry Acidic Basic Hydrophobic Neutral Polar
Epitope
Non-epitope
B
AAfrequency in non-epitope
AAfrequency in epitope
0.00
0.05
0.10
0.15
L
I
Y K
S V
F
T
A
N
D R
E
P
G
M
H
Q
C
W


A
Importance
B
ROC curve
True positive rate
False positive rate
AUC = 0.752
AUC = 0.792
AUC = 0.812
C
ROC curve
True positive rate
False positive rate
AUC = 0.754
AUC = 0.779


A
Importance
0
10
20
30
40
shadowMin
shadowMean
C27
C25
shadowMax
C14
C13
C22
C7
C2
C9
C16
C23
C1
C5
C4
C15
C21
C26
C20
C10
C17
C11
C8
C3
C19
C6
C12
C18
C24
B
ROC curve
True positive rate
False positive rate
0.0
0.2
0.4
0.6
0.8
1.0
AUC = 0.785